Evidence map›Paper›PMID 22936664›Full record

ReviewBlood2012

Aging and neoteny in the B lineage.

Doron Melamed, David W Scott

Abstract readReview
In one paragraph

Review in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Immune aging in diabetes and its implications in wound healing.Clinical immunology (Orlando, Fla.) · 2019
    Review
  7. Article
  8. B cells in the aging immune system: time to consider B-1 cells.Annals of the New York Academy of Sciences · 2015
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Doron MelamedDepartment of Immunology, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel. melamedd@tx.technion.ac.il.
David W Scott

Funding

Induction of Tolerance to Factor VIII in HemophilicR01HL061883 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SCOTT, DAVID WILLIAM · 1998 to 2012
$3.7M
GENE THERAPEUTIC APPROACH FOR TOLERANCE INDUCTIONR01AI035622 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SCOTT, DAVID WILLIAM · 1997 to 2013
$3.7M
Mechanisms of Tolerance Induction to FVIII in HemophiliaR56HL061883 · NHLBI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI SCOTT, DAVID WILLIAM · 2014 to 2014
$380k
NHLBI NIH HHS HL061883NHLBI NIH HHS R01 HL061883NHLBI NIH HHS R56 HL061883NIAID NIH HHS AI035622NIAID NIH HHS R01 AI035622
6 · The paper itself

Abstract

Aging and the physiologic decline of tissues and cells were once thought to be irreversible. However, recent studies suggest that various tissues, especially parts of the hematopoietic system, can be rejuvenated. Here we review potential mechanisms for this process and how they may be used to reverse age-related disorders and aging in general. We propose the novel hypothesis that altering the homeostatic process during cellular depletion can reverse aging in the hematopoietic system.

Indexed as

Models, BiologicalAgingAnimalsAntibodies, Monoclonal, Murine-DerivedB-LymphocytesCell DivisionCell LineageGenes, p16Genetic TherapyHematopoietic Stem CellsHematopoietic SystemHomeostasisHumansLymphocytesLymphocyte SubsetsLymphopoiesisAntibodies, Monoclonal, Murine-DerivedBub1 spindle checkpoint proteinProtein Serine-Threonine KinasesRituximab

Identifiers

PMID22936664
PMCPMC3543944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.